Voyager Therapeutics(US:VYGR)2025-05-06 20:01Financial Performance - Voyager ended Q1 2025 with a cash position of $295 million, expected to provide runway into mid-2027[2] - Net loss for Q1 2025 was $31.0 million, compared to a net loss of $11.3 million in Q1 2024, representing an increase of 174.0%[8] - Voyager's total operating expenses for Q1 2025 were $41.2 million, compared to $35.7 million in Q1 2024, an increase of 15.2%[8] - Voyager's total assets decreased to $353.2 million as of March 31, 2025, down from $393.1 million as of December 31, 2024[19] Revenue - Collaboration revenue for Q1 2025 was $6.5 million, down from $19.5 million in Q1 2024, a decrease of approximately 66.8%[8] - GAAP collaboration revenue for Q1 2025 was $6.473 million, a decrease from $19.516 million in Q1 2024[23] - Net collaboration revenue for Q1 2025 was $4.845 million, down from $16.338 million in Q1 2024[23] Expenses - Research and development expenses increased to $31.5 million in Q1 2025 from $27.1 million in Q1 2024, a rise of 16.3%[8] - General and administrative expenses rose to $9.6 million in Q1 2025 from $8.6 million in Q1 2024, an increase of 11.6%[8] - Total research and development expenses for Q1 2025 increased to $31.526 million, compared to $27.092 million in Q1 2024[23] - Net research and development expenses for Q1 2025 were $29.898 million, up from $23.914 million in Q1 2024[23] - Reimbursable research and development services incurred in Q1 2025 amounted to $1.628 million, down from $3.178 million in Q1 2024[23] Clinical Development - The company anticipates IND submissions for the Neurocrine-partnered FA and GBA1 programs in 2025[3] - Initial tau PET imaging data from the MAD clinical trial of VY7523 is expected in the second half of 2026[3] - A single IV dose of VY1706 achieved up to 73% knockdown of tau mRNA in NHPs[5]